GlobeNewswire

InnoStudio Continues To Push Chemistry Towards The Stars

Dela

Space Chemistry Special Session to be held at International Astronautical Congress for first time

 

BUDAPEST, Hungary and BOSTON, May 10, 2018 (GLOBE NEWSWIRE) -- InnoStudio is pleased to announce that its proposal for holding a Special Session on Space Chemistry at the 69th International Astronautical Congress entitled "Space Chemistry: a Key to Fostering Space Exploration" has been accepted. This is the first time that a special session on this topic will be held at such a prestigious event. The congress will take place in Bremen, Germany between the 1st and 5th October 2018.  The above special session will be held as part of the technical programme. We believe that the acceptance of this topic as a special session greatly emphasizes the importance of Space Chemistry for the future of the Space Industry.

IAC2018 Special Sessions are to supplement the regular technical programme of the congress and provide a sample of the state-of-the-art research and development in both academia and industry in special, novel, challenging and emerging topics in the field of space. Special Sessions emphasize multi-disciplinary and transversal aspects, as well as cutting-edge topics of space exploration.

The list of accepted Special Sessions can be found at http://www.iafastro.org/events/iac/iac- 2018/technical-programme/special-sessions/.

We are also happy to announce that InnoStudio's experts will give a presentation at the 3rd Space Chemistry Symposium - "Chemistry in Space & Past, Present & Future", which will be held on the 254th ACS National Meeting & Exposition between 19th and 23rd August 2018 in Boston, US.

The topics of the symposium will cover a wide range of pioneering chemistry technologies from space perspectives, including flow chemistry, nanomaterials and new platforms for microgravity research onboard the International Space Station. These innovations are expected to make an essential contribution towards facilitating space exploration missions and human expeditions.

Finally, a perspective article written by InnoStudio's space experts was published in the Journal of Flow Chemistry. The paper summarizes the state of the art of space chemistry, analyzes the suitability of flow chemistry in an extraterrestrial environment, and discusses some of the challenges and opportunities in space chemistry.

Read the article here: https://akademiai.com/doi/pdf/10.1556/1846.2017.00033

For more information please contact Richard Jones, CEO: richard.jones@innostudio.org

About InnoStudio Inc.

InnoStudio Inc. was founded in 2013 as a spin-off of Cominnex Inc. The companies belong to Darholding, which is a leading innovation house specialized on innovative spin-out companies. The three pillars of success are: a strong scientific background, a wide network of relationships with top companies and a special management approach.

InnoStudio Inc. is specialized in innovating on high risk, high gain fields with high importance such as:

· Nanotechnology: applying dynamic flow systems for generating nanoparticles, primarily for life science and chemistry related fields. e.g. Innostudio formulates first-tier agrochemical substances in collaboration with Agrothetis Inc.

· Artificial Intelligence and Chemometrics: adapting them for developing software solutions needed by sister corporations in the Darholding network and other users for pharma and bioscience related discovery, flow chemistry, microfluidics and nanotechnology.

· Improving bioavailability of natural products: adapting complex physicochemical solutions, including nanotechnology, for enhancing and optimizing skin penetration of natural products in aromatherapy, cosmetics and other flavour and fragrance fields.

· Space Chemistry: bringing experimental chemistry to space by incubating a research and development team of specialists.

Together with two other companies of the Darholding network, ThalesNano Inc. and ComInnex Inc.  the Space Chemistry Studio of InnoStudio is working on the Space Chemistry Project for shaping the future of chemistry in space. The Space Chemistry Project was founded by the Flow Chemistry Society on Switzerland in 2014 for bringing chemistry to the space. Today it has more than 40 members from 5 continents. (http://spaceflow.org/)




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: InnoStudio Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum